Communicators

BioChem Solutions Inc. inks sub-license for India sales

Frankfurt, Germany -- BioChem Solutions Inc. today announced execution of an agreement to manufacture and distribute for sale its arthritis, HIV/AIDS and related medications throughout the Republic of India.

Tropical II Ventures Ltd. was granted exclusive production and marketing rights in India for all BioChem Solutions products. With a population of 1.15 billion, India is the world's second-largest marketplace behind only China.

BioChem Solutions holds the worldwide master license to produce and distribute all products that incorporate the patented product Trioxolane as an active ingredient. Its first products are the trademarked derivatives Arthromir and Alphamir. Preliminary medical studies strongly suggest that Arthromir has significant potential in the clinical management of rheumatoid arthritis, while Alphamir shows similar promise in the treatment of HIV/AIDS patients.

The initial term of Tropical II Ventures' agreement is five years, during which the company also is authorized to further license additional distributors in India and to market BioChem Solutions products for private-label marketing. BioChem Solutions will receive a 10% gross royalty fee on all Tropical II Ventures sales in India.

BioChem Solutions also holds the global master license to produce and market medications derived from the patented product Diperoxide. In trials to date, both Trioxolane and Diperoxide derivatives have shown significant improvement in the function of the human immune system using a variety of indicators.

The use of these derivatives has potential in destroying tumor cells and harmful micro-organisms such as bacteria, viruses, parasites and fungi. Treatment is non-toxic and has shown no adverse side effects. Moreover, these products reinforce natural immune systems in combating harmful agents and regulating the beneficial production of serotonin, prostaglandin and inflammatory interleukins.

Company representatives recently concluded their second multi-city trip to India, exploring opportunities for commercial development of its patented products and potential business alliances.

Company Contact: www.biochemsolutiosinc.com -- info@biochemsolutionsinc.com

Company Address: 80 SW 8th Street, Suite 2000, Miami, FL 33130, USA

Share Information: WKN: A0J36E, ISIN: US0909651046

Investor Relations: Connecting Markets GmbH, E. Akay – akay@cmir.de
FON + 49 (0) 69 – 21 65 59 10 FAX + 49 (0) 69 – 21 65 59 11

Included in this release are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Although the company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations reflected in such forward-looking statements will prove to have been correct. The company's actual results could differ materially from those anticipated in the forward-looking statements. The Company undertakes no obligation to update forward-looking statements to reflect subsequently occurring events or circumstances.

Mitteilung übermittelt durch IRW-Press.com. Für den Inhalt ist der Aussender
verantwortlich.
Kostenloser Abdruck mit Quellenangabe erlaubt.